tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Michael King, 118 are a BUY (99.16%), 1 are a HOLD (0.84%).
Analyst Michael King, currently employed at RODMAN & RENSHAW, carries an average stock price target met ratio of 50.73% that have a potential upside of 50.02% achieved within 301 days. Previously, Michael King worked at BENCHMARK, JMP, HC WAINWRIGHT, BENCHMARK.
Michael King’s has documented 237 price targets and ratings displayed on 31 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on AGEN, Agenus at 28-Sep-2026.
Analyst best performing recommendations are on NTLA (INTELLIA THERAPEUTICS).
The best stock recommendation documented was for NTLA (INTELLIA THERAPEUTICS) at 6/28/2021. The price target of $171 was fulfilled within 3 days with a profit of $37.57 (28.16%) receiving and performance score of 93.86.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy Since 20-Sep-2022
$345
$112.32 (48.27%)
$350
Buy Since 15-May-2025
$369
$136.32 (58.59%)
$375
10 days ago
(30-Sep-2026)
9/12 (75%)
$122.26 (49.55%)
30
Buy Since 12-Feb-2021
$455
$222.32 (95.55%)
$455
19 days ago
(21-Sep-2026)
24/43 (55.81%)
$210.68 (86.23%)
682
Hold Since 31-Mar-2026
$260
$27.32 (11.74%)
$330
1 months 2 days ago
(08-Sep-2026)
3/3 (100%)
$-0.1 (-0.04%)
6
Buy Since 21-Mar-2025
$318
$85.32 (36.67%)
$583
1 months 21 days ago
(19-Aug-2026)
34/36 (94.44%)
$75.39 (31.07%)
273
Which stock is Michael King most bullish on?
What Year was the first public recommendation made by Michael King?
